KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R −/− Mice
- 1 July 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 33 (7) , 1505-1512
Abstract
Objective—: Sphingosine 1-phosphate (S1P) partly accounts for antiatherogenic properties of high-density lipoproteins. We previously demonstrated that FTY720, a synthetic S1P analog targeting all S1P receptors but S1P receptor type 2, inhibits murine atherosclerosis. Here, we addressed the identity of S1P receptor mediating atheroprotective effects of S1P. Approach and Results—: Low-density lipoprotein receptor–deficient mice on cholesterol-rich diet were given selective S1P receptor type 1 agonist KRP-203 (3.0 mg/kg per day; 6 and 16 weeks). KRP-203 substantially reduced atherosclerotic lesion formation without affecting plasma lipid concentrations. However, KRP-203 induced lymphopenia, reduced total (CD4 + , CD8 + ) and activated (CD69 + /CD8 + , CD69 + /CD4 + ) T cells in peripheral lymphoid organs, and interfered with lymphocyte function, as evidenced by decreased T-cell proliferation and interleukin-2 and interferon-γ production in activated splenocytes. Cyto- and chemokine (tumor necrosis factor-α, regulated and normal T cell expressed and secreted) levels in plasma and aortas were reduced by KRP-203 administration. Moreover, macrophages from KRP-203–treated mice showed reduced expression of activation marker MCH-II and poly(I:C)-elicited production of tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin-6. In vitro studies demonstrated that KRP-203 reduced tumor necrosis factor-α, interleukin-6, and interferon-γ–induced protein-10 production; IκB and signal transducer and activator of transcription-1 phosphorylation; and nuclear factor κB and signal transducer and activator of transcription-1 activation in poly(I:C)-, lipopolysaccharide-, or interferon-γ–stimulated bone marrow macrophages, respectively. Conclusions—: Present results demonstrate that activation of S1P signaling pathways inhibit atherosclerosis by modulating lymphocyte and macrophage function and suggest that S1P receptor type 1 at least partially mediates antiatherogenic effects of S1P.Keywords
This publication has 53 references indexed in Scilit:
- Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid ReceptorsChemical Reviews, 2011
- Pharmacological relevance and potential of sphingosine 1‐phosphate in the vascular systemBritish Journal of Pharmacology, 2011
- Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein MProceedings of the National Academy of Sciences, 2011
- Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytesKidney International, 2011
- The Expression and Functions of Toll-Like Receptors in AtherosclerosisMediators of Inflammation, 2010
- The alliance of sphingosine-1-phosphate and its receptors in immunityNature Reviews Immunology, 2008
- High Density Lipoprotein-associated Sphingosine 1-Phosphate Promotes Endothelial Barrier FunctionJournal of Biological Chemistry, 2008
- “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic TargetsPharmacological Reviews, 2008
- Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high‐density lipoproteinsBritish Journal of Pharmacology, 2007
- CHEMOKINES, SPHINGOSINE-1-PHOSPHATE, AND CELL MIGRATION IN SECONDARY LYMPHOID ORGANSAnnual Review of Immunology, 2005